# Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

> **NCT00678327** · PHASE3 · COMPLETED · sponsor: **University College, London** · enrollment: 1202 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** bleomycin sulfate
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** pegfilgrastim
- **DRUG:** cyclophosphamide
- **DRUG:** dacarbazine
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** prednisolone
- **DRUG:** procarbazine hydrochloride
- **DRUG:** vinblastine sulfate
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00678327
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-29
- **Primary completion:** 2016-01-31
- **Final completion:** 2024-05-01
- **Target enrollment:** 1202 (ACTUAL)
- **Last updated:** 2024-05-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00678327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00678327, "Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00678327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*